Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Thyroid Neoplasms × Epinephrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Thyroid Neoplasms 1 Pain, Postoperative 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Malignant Neoplasms of Male Genital Organs 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Hairy Cell 1 Leukemia 1 Hodgkin Disease 1 Goiter 1

Interventions

vandetanib 7 lenvatinib 5 cabozantinib 4 Sunitinib 4 Sorafenib 4 AZD 6244 3 selpercatinib 2 durvalumab 2 alectinib 2 Triiodothyronine 2 Thyroxine 2 Paclitaxel 2 Iodine-131 2 Everolimus 2 Bortezomib 2 Axitinib 2 tremelimumab 1 tipifarnib 1 temsirolimus 1 tanespimycin 1 sapanisertib 1 regorafenib 1 pralsetinib 1 ponatinib 1 perflutren 1 pazopanib 1 pasireotide 1 methyl N-acetylsibirosaminide 1 gallium 68 PSMA-11 1 fosbretabulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02112370 2017-08-04

REBT

Seoul National University Hospital

Phase 3 Completed

148 enrolled 17 charts

Goiter, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡